|
 |
CopaxoneThis page contains recent news articles, when available, and an overview of Copaxone but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.She knows too well the side effects of MS drugs such as copaxone, which she took to treat her relapsing-remitting MS. Raymond ended up in hospital for two ... Sudbury Star Teva Pharmaceutical historisch günstig - Der Aktionär - 06 Jan 2010 Daneben habe Teva Pharmaceutical mit Copaxone auch eine erfolgreiche Eigenentwicklung auf den Markt gebracht. Die Aktie von Teva Pharmaceutical ist ... Stock World 5 Stocks That Just Won't Quit - Jan 4, 2010 On the other hand, if the warned-of genericization of Copaxone comes to pass, and the best Teva is able to manage is 7% long-term growth, look out below. ... Motley Fool Julie's Low Dose Naltrexone Journal: Stopping LDN (for Now) - Jan 4, 2010 I am still on Copaxone. I think I will go through the winter and early spring LDN-free (my MS symptoms are always more mild in this weather), then restart ... About - News & Issues (blog) Teva buys rights to prostate cancer drug - Dec 21, 2009 However, its brand drug Copaxone, used to treat relapsing-remitting multiple sclerosis, is responsible for about 20% of its sales. In 2008, for instance, ... Ha'aretz Momenta drops drug from deal with Novartis' unit - Dec 18, 2009 Both companies continued their collaboration on blood thinner M-Enoxaparin and a copy-cat version of multiple sclerosis treatment Copaxone, it said. ... Reuters Barclays: Aggressively buy Teva shares through year-end - Dec 24, 2009 As for Copaxone, Silver says that if the results from a recently-completed six-month pain perception study prove positive of a low dosage version (0.5 ml ... Globes Clinical Trial Examines Drug's Potential for Protecting the Optic Nerve - Dec 28, 2009 For six months, study subjects will receive either a placebo ( no active ingredient ) or Copaxone injections ( glatiramer acetate ), a drug used to treat MS ... Media Newswire (press release) Piper Jaffray Initiates Coverage on Teva Pharmaceutical (TEVA) with an ... - Dec 10, 2009 We believe strong EPS growth (we estimate a 5-year CAGR of 7%) is sustainable, with or without a Copaxone generic in 2014. We further believe that Teva will ... StreetInsider.com (subscription) Acorda's Fampridine: The First FDA Approval to Help MS Patient's Walk - Dec 14, 2009 Unlike the disease modifying drugs (Copaxone, Tysabri and the interferons) Fampridine SR was effective irrespective of MS subtype (relapsing remitting, ... Gerson Lehrman Group Markets in Brief - Jan 3, 2010 Citibank analyst John Boris expects litigation over Teva's proprietary drug Copaxone for the treatment of multiple sclerosis to result in a favorable ... Ha'aretz Bigger in Japan - Dec 24, 2009 ...presented in 2008, and both deals are intended to ensure the company's future growth, mainly by reducing Teva's heavy dependence on Copaxone for profit. ... Globes Strong tailwinds could set generic drug makers flying - Dec 15, 2009 Teva has patented drugs of its own, the largest being Copaxone for multiple sclerosis. The risk factor here is that Copaxone is scheduled to go off patent ... Globe and Mail Israel stocks up; Teva gets lift; Givot finds oil - Dec 24, 2009 Silver also predicted Teva will describe its assumptions for Copaxone, its flagship multiple-sclerosis treatment, to 2015, "including [the] competitive ... MarketWatch Medical marijuana attorney Rob Corry: "The future is here" - Dec 18, 2009 These medications include Copaxone, Gabapentin, Cyclobenzaprine, Meloxicam, Sertraline, Advair, and Mirapex. With the addition of medical marijuana to her ... Westword (blog) Sanofi Pulls the Plug on Two Drugs: Biotech's Latest Mishaps - Dec 24, 2009 The two companies continue to collaborate on the blood thinner M-Enoxaparin and a generic version of the multiple sclerosis drug Copaxone. ... Seeking Alpha (blog) Market report / Africa Israel stock swings down 10% - Dec 21, 2009 Presently, this portfolio contains two - Copaxone for multiple sclerosis and Azilect for Parkinson's Disease. The new drug is OXG-011 and it's being ... Ha'aretz Markets in Brief - Dec 16, 2009 Piper thinks Teva can weather a generic competitor to Copaxone, the Israeli drug company's proprietary drug for multiple sclerosis. ... Ha'aretz Under the microscope: Israeli biomedical research - Dec 12, 2009 Arnon, a co-developer of the multiple sclerosis drug Copaxone, which significantly reduces the frequency and severity of attacks of the as-yet-incurable ... Jerusalem Post Potential of a drug to seemingly protect the optic nerve to be examined - Dec 24, 2009 These individuals will be enrolled for six months where they will receive either a placebo (no active ingredient) or Copaxone injections (glatiramer ... HealthJockey.com Teva Pharmaceuticals Started as “Overweight†at Piper Jaffray (TEVA) - Dec 11, 2009 We believe strong EPS growth (we estimate a 5-year CAGR of 7%) is sustainable, with or without a Copaxone generic in 2014. We further believe that Teva will ... NASDAQ Wall St Sense Progressive Report on Healthcare, Basic Materials and Financial ... - Dec 19, 2009 However, we are concerned for TEVA as Teva's Copaxone is challenged by Mylan. The ANDA, filed by generic company Mylan Inc. (MYL) was. ... PR-CANADA.net (press release) News: ISRAEL PHARMACIE : Teva prend des parts dans une société de génériques ... - Dec 26, 2009 Les performances du groupe sont liées à la forte dynamique de la Copaxone (glatiromère), traitement indiqué pour réduire la fréquence des poussées chez les ... IsraelValley A Natale manca farmaco per la sclerosi - Dec 29, 2009 ...vi mando questa mail per segnalare che ogni fine anno, tra dicembre e gennaio viene a mancare la distribuzione di un farmaco (Copaxone) per la terapia ... Il Messaggero Teva Pharmaceutical einsteigen - Dec 18, 2009 Ergebnisse davon seien beispielsweise das Parkinson-Medikament Azilect sowie Copaxone zur Behandlung Multipler Sklerose (MS). Copaxone habe im dritten ... newratings.de הסקירה השבועית של ×¡×¤×•× ×¡×¨ - Dec 13, 2009 ...×‘× ×•×¡×£ מפתחת טבע ומשווקת בעצמה וביחד ×¢×? ×?חרי×?, ×?ת מוצרה הייחודי הר×?שון ×”-COPAXONE, לטיפול בטרשת × ×¤×•×¦×”. ×‘×™× ×•×?ר 2004 הושל×? המיזוג ×¢×? SICOR, ×•×‘×™× ×•×?ר 2006 הושלמה ... Economist Teva Pharmaceutical Industries Limited - Financial And Strategic Analysis ... - 14 Nov 2009 It also received approval of Risperdal oral solution, Copaxone and Imitrex Tablets. Teva Pharmaceutical Industries Limited - Financial and Strategic ... OfficialWire (press release) Teva wants to expand Copaxone patent lawsuit - Nov 13, 2009 Teva is now saying the two companies are violating 10 patents on Copaxone, up from seven claimed in a lawsuit filed by Teva in 2008. ... Ynetnews Teva Pharm 3Q Profit Up; Copaxone, Respiratory Strong - Nov 3, 2009 Sales of the multiple-sclerosis treatment Copaxone rose 38% in the quarter to $776 million. Within Teva's respiratory business, sales totaled $243 million, ... Wall Street Journal Teva seeks to widen Copaxone patent suit - Nov 10, 2009 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) wants to add three more patents to its Copaxone patent-infringement lawsuit filed against ... Globes Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone - Nov 6, 2009 Teva alleges patent infringement of its flagship multiple sclerosis drug Copaxone, and reiterates that intellectual property rights covering chemical ... BNET Teva files amended complaint against Momenta and Sandoz - Nov 12, 2009 Teva originally filed suit against Momenta and Sandoz in August 2008 for infringement of multiple patents, covering the chemical composition of Copaxone, ... American Chronicle Zacks Analyst Blog Highlights: Baker Hughes Inc., BJ Services, Teva ... - Nov 5, 2009 Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, ... Reuters QLT, Novartis restructure Visudyne deal; Teva launches Copaxone patent battle ... - Oct 19, 2009 ...alleging that Mylan's application to market a copycat version of Teva's multiple sclerosis drug Copaxone was infringing certain patents. ... FiercePharma Tue: TASE seesaws to flat close - Nov 10, 2009 Africa-Israel fell on its failure to pay its bonds, while Teva rose as it fights to protect Copaxone. The Tel Aviv Stock Exchange (TASE) was flat today. ... Globes Teva Reports Third Quarter 2009 Results - Nov 2, 2009 Record global in-market sales of Copaxone® of $776 million, up 38% compared to the third quarter of 2008. Copaxone® continues to be the leading MS therapy ... Reuters Teva Sues Mylan to Protect Generic MS Drug - Nov 10, 2009 Teva filed the suit recently in the US District Court for the Southern District of New York in response to the Mylan ANDA filing for generic Copaxone ... FDA news (subscription) Markets in Brief - Nov 10, 2009 The patents concern the characterization of Copaxone's active ingredient (glatiramer acetate). The original claim, filed in August last year, ... Ha'aretz 5-Star Stocks Poised to Pop: Teva - Oct 22, 2009 Current market angst over loss of Copaxone patent and worry about indigestion from Barr acquisition are holding the lid on this stock; short-term static, ... Motley Fool Ifs, ands, and buts for Teva - Nov 3, 2009 He said that most of Copaxone's growth came from winning market share, and that it had a 38% share of the US multiple sclerosis treatment market and 30% of ... Globes Hapoalim: Teva to make acquisition in H1 of 2010: Gilad Sarig: There is little ... - Oct 27, 2009 This will hurt Teva, as Copaxone accounts for about a third of its total revenue. Teva argues that its Copaxone patents are valid through 2014, ... Trading Markets (press release) Target: Cargo Theft - Oct 21, 2009 Forsaith added that maintaining temperature for drugs such as insulin for diabetics or copaxone for suffers of multiple sclerosis is absolutely critical. ... Fleet Owner Julie's Low Dose Naltrexone Journal: Month 6 - Nov 2, 2009 As those of you who have been following my LDN journey know, I have relapsing-remitting MS and have been taking Copaxone for over 3 years. ... About - News & Issues (blog) Six House killer hospitalized - Oct 21, 2009 George said Piscopo is dependent upon Copaxone injections and steroids to cope with his MS symptoms. “He's always stiff, but if he doesn't take the ... Boston Herald MS drug brakes progression to full-blown disease - Nov 5, 2009 The treatment, glatiramer acetate, marketed as Copaxone, was tested in 16 countries among 481 patients with a tell-tale lesion in the central nervous system ... Regina Leader-Post Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript - Nov 6, 2009 I'll now discuss M356, our generic version of Teva's Copaxone, which we are developing in collaboration with Sandoz. Our characterization technology has ... Seeking Alpha (blog) New drug therapies and promising research offer hope to MS sufferers - Nov 13, 2009 ..."All five" — Avonex, Betaseron, Copaxone, Rebif and Tysabri — "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Canada.com Survey: Affluent Areas Have Cheaper Drugs - Oct 29, 2009 Among the findings in the August survey: A store in Franklin was selling the multiple sclerosis drug Copaxone for more than $2800. ... WSMV Teva sues Mylan over attempt to make multiple sclerosis generic drug - Oct 20, 2009 The Israeli drug maker filed suit against Mylan and Natco Pharma in the US District Court for the Southern District of New York over Copaxone (glatiramer ... Drug Store News (blog) Omnicare, Inc. Q3 2009 Earnings Call Transcript - Nov 6, 2009 ...toward the use of higher acuity drugs such as hydrocele [ph], biologic drugs such as Copaxone and branded drugs with new indication such as (inaudible). ... Seeking Alpha (blog) Israel stocks snap 4-session loss streak; Teva, Perrigo eyed - Nov 2, 2009 ...strength in the company's inhaler business, accelerated growth in women's-health sales, and stable" sales of the multiple-sclerosis medication Copaxone. ... MarketWatch Markets in Brief - Nov 3, 2009 Global sales of multiple sclerosis treatment Copaxone rose 38% to $776 million and strong sales of inhaler ProAir helped sales of Teva's global respiratory ... Ha'aretz Boycott Israel? Norwegian University Must Decide - Nov 8, 2009 If any of them or their families suffers from multiple sclerosis, let them refuse to take Copaxone. If they have Parkinson's disease, stop the Azilect. ... Huffington Post (blog) Stocks in the news: Burlington Northern, Johnson & Johnson, Black & Decker - Nov 3, 2009 Teva Pharmaceutical Industries Ltd. (TEVA) said Tuesday its profit rose 3 percent in the third quarter on sales of its MS drug Copaxone as well as other ... Daily Finance (blog) More Tysabri Problems; Time for a Biogen-Idec Credibility Check - Oct 30, 2009 Data from a 15-year ongoing Copaxone prospective study demonstrating patients treated for 10 and 15 years with the drug had significant reduction in disease ... BNET Research offers new hope to MS sufferers - Nov 10, 2009 ..."All five"--Avonex, Betaseron, Copaxone, Rebif and Tysabri-- "are drug therapies that attenuate the disease by helping control the intensity and frequency ... Calgary Herald Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009 - Oct 30, 2009 Copaxone® posted third-quarter net sales of euro 118 million, a rise of 20.0%. The end of commercialization of the product by sanofi-aventis in North ... Reuters All Tysabri, All the Time - Oct 20, 2009 Keep in mind that Tysabri reduces flareups better than other multiple sclerosis drugs such as Teva Pharmaceutical's (Nasdaq: TEVA) Copaxone, ... Motley Fool US Stock Futures Point To Sharply Lower Opening - Nov 3, 2009 Ltd. (TEVA) posted higher profit for the third quarter, boosted by strong sales of its multiple sclerosis drug Copaxone and Albuterol inhaler ProAir. ... RTT News Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release ... - Nov 3, 2009 ...the effects of competition on our innovative products, especially Copaxone sales, dependence on the effectiveness of our patents and other protections ... Reuters Pharm firms suffer drop after MS drug comes under fire - Oct 25, 2009 Teva's Copaxone, for instance, is administered by daily injection. Also, Tysbari is considered more effective than other medications and among other uses, ... Ha'aretz NEW YORK, Oct 19 (Reuters) - Some US stocks to watch on Monday: - Oct 19, 2009 The company sued rival Mylan Inc, alleging that Mylan's application to market a copycat version of Teva's multiple sclerosis drug Copaxone was infringing ... Forbes US stock market opening report (November 10, 2009, Tuesday) - Nov 10, 2009 ...against Momenta Pharmaceuticals (MNTA)/Sandoz to include patent infringement of three additional patents related to the characterization of Copaxone. ... Stock Markets Review Stocks Under $10 Weekly Summary - Oct 23, 2009 First, Mylan was sued by Teva Pharmaceuticals (TEVA:Nasadq) for infringing on Teva's patent for the multiple sclerosis drug Copaxone. ... TheStreet.com (subscription) STOCKS NEWS US-Human Genome to seek drug approval in Q4 - Oct 19, 2009 ...alleging that the company's application to market a copycat version of its multiple sclerosis drug Copaxone was infringing certain Teva patents. ... Interactive Investor Tuesday's biggest gaining and declining stocks - Nov 3, 2009 ...reported that third-quarter net income rose 2.9%, with 25% higher sales driven by its flagship drug, Copaxone, and by its ProAir albuterol inhaler. ... Middle East North Africa Financial Network My Two Healthcare Favorites - Nov 3, 2009 Teva's largest selling generic drug, Copaxone, is used to treat multiple sclerosis. The company's aggressive acquisition and product development programs ... Seeking Alpha (blog) Markets in Brief - Oct 28, 2009 He also predicts that sales of Copaxone, Teva's proprietary drug for multiple sclerosis, will pass the $700 million-mark for the first time in the third ... Ha'aretz Clarification on anti-cancer drug triggers rebound in Natco Pharma - Oct 20, 2009 US drug regulator's approved the new drug application from its partner Mylan Inc for a generic version of Teva Pharmaceutical's blockbuster Copaxone. ... India Infoline.com Court Report - Oct 25, 2009 Copaxone® (glatiramer acetate injection, used for the reduction of frequency of relapses in patients with relapsing-remitting multiple sclerosis). ... Patent Docs (blog) Business news briefs - Oct 19, 2009 Industries sued Mylan for patent infringement on Friday over Mylan's application to market a generic version of Teva's multiple sclerosis drug Copaxone. ... Pittsburgh Post Gazette Updates, advisories and surprises - Nov 2, 2009 Sales of its flagship drug, the multiple-sclerosis treatment Copaxone, rose 38% in the quarter to $776 million. Sales of Azilect for Parkinson's disease ... MarketWatch Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy ... - Oct 30, 2009 Copaxone posted third-quarter net sales of EUR 118 million, 18% higher than last year. Sanofi-Aventis also said that its OTC business generated net sales of ... Trading Markets (press release) Reaching for the sky - Oct 23, 2009 There are also new medications like Copaxone, which Booker takes. “It's a completely different disease,â€? Berkovich said. “That's why I usually say to my ... Glendale News Press Sentiment Upbeat Ahead Of Housing Report - RTTNews Daily Market Analysis - Oct 19, 2009 ...that it has filed a lawsuit against Mylan and Natco Pharma for patent infringement over a generic version of its multiple sclerosis drug, Copaxone. ... Trading Markets (press release) Gewinnzuwachs beim israelischer Teva - Nov 3, 2009 Tel Aviv - Der israelische Arzneimittelhersteller Teva hat im abgelaufenen Quartal von der starken Nachfrage nach seinem Multiple-Sklerose-Mittel Copaxone ... derStandard.at US to review Momenta's generic of Teva's Copaxone - Jul 11, 2008 By Lewis Krauskopf. NEW YORK (Reuters) - Momenta Pharmaceuticals Inc (MNTA.O) said on Friday US regulators had accepted for review its generic version of ... Reuters UK Teva CEO doesn't see generic Copaxone soon -paper - Jul 14, 2008 TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' (TEVA.O) multiple sclerosis drug Copaxone before 2014 ... Reuters Teva's Copaxone cuts risk of developing MS--study - Dec 3, 2007 NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's (TEVA.O) Copaxone reduced the risk of patients developing multiple sclerosis after they ... Reuters Teva sues Novartis, Momenta over Copaxone patent - Aug 28, 2008 By Bill Berkrot. NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd sued Swiss drugmaker Novartis AG and Momenta Pharmaceuticals Inc on Thursday, ... Reuters Teva Gains in Profits but Ivax, Its Takeover Target, Falls Back - Aug 2, 2005 Sales of the brand-name medicine Copaxone helped Teva as its North American ... Teva said revenue from Copaxone, one of two branded drugs the company makes ... New York Times Teva may face generic rival to Copaxone - May 20, 2007 By Robert Daniel, MarketWatch. TEL AVIV (MarketWatch) -- Teva Pharmaceutical Industries Ltd. may face its first generic competition for its first branded ... MarketWatch Teva says Q1 sales of Copaxone MS drug rise 35 pct to $542 mln - Apr 30, 2008 LONDON (Thomson Financial) - Teva Pharmaceutical Industries Ltd. said global first-quarter in-market sales of its multiple sclerosis drug Copaxone rose 35 ... Forbes Merck KGaA's Rebif, Teva's Copaxone similar-study - Oct 10, 2007 FRANKFURT, Oct 10 (Reuters) - Merck KGaA's (MRCG.DE) Rebif multiple-sclerosis drug is not superior to rival Teva's (TEVA.O) Copaxone, a study obtained by ... Reuters Teva Ends Work on Oral Copaxone - Mar 21, 2006 By Robert Steyer 03/21/06 - 01:58 PM EST. Teva Pharmaceutical Industries (TEVA Quote), the maker of the popular multiple sclerosis treatment Copaxone, ... TheStreet.com - TheStreet.com (subscription) Copaxone pushes Teva profits past $1b. mark in 2005 - Mar 1, 2006 By SHARON WROBEL. Teva Pharmaceutical Industries, the world's largest manufacturer of generic drugs on Tuesday reported a 9 percent increase in fourth ... Jerusalem Post Out of the Gate: Teva drops on Copaxone results - Jul 7, 2008 NEW YORK—Shares of Teva Pharmaceutical Industries Ltd. fell Monday after the company posted disappointing results from a higher-dose trial of multiple ... Boston Globe Teva hopes to repeat Copaxone success with Parkinson's drug - May 19, 2006 By JUDY SIEGEL-ITZKOVICH. Teva Pharmaceutical Industries is hopeful that the second proprietary drug it has developed - Agilect (or Azilect, ... Jerusalem Post Generic Copaxone deal boosts Mylan, sinks Teva - Jun 10, 2008 NEW YORK --Shares of Teva Pharmaceutical Industries Ltd. fell Tuesday after its blockbuster multiple sclerosis drug Copaxone faced the possibility of a ... Boston Globe Teva sees Copaxone as leading MS drug in 2008 - Feb 12, 2008 TEL AVIV, Feb 12 (Reuters) - Israel's Teva Pharmaceutical Industries (TEVA.TA) (TEVA.O) said on Tuesday it expects its Copaxone to become the leading drug ... Reuters Betting On Elan's Second Resurrection - Jun 17, 2005 In that drug's largest published two-year clinical trial of 251 relapsing patients, Copaxone only reduced the relapse rate by 29% compared to placebo. ... Forbes Teva sabotaged drug to save Copaxone sales, claims ProNeuron - Dec 4, 2007 Teva Pharmaceuticals (TASE, Nasdaq: TEVA) is not only hurting ProNeuron Biotechnologies and its rights. It's hurting the public of patients suffering from ... Ha'aretz Teva: Study finds Copaxone reduced annual relapse rates in MS patients - Apr 10, 2008 NEW YORK (Thomson Financial) - Teva Pharmaceutical Industries Ltd. Thursday said a three-year study evaluating the effects of multiple sclerosis drug ... Forbes Teva says Q2 global in-market sales of Copaxone rose 22 pct to 353... - Aug 2, 2006 LONDON (AFX) - Teva Pharmaceutical Industries Ltd said global in-market sales of multiple sclerosis therapy Copaxone rose 22 pct from the year-earlier ... Forbes Teva Pharmaceutical posts 6 percent rise in third-quarter profit,... - Nov 9, 2005 Global sales of Copaxone increased 27 percent over a year ago to $307 million, ... According to IMS Health Inc., which tracks prescription trends, Copaxone ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com MS Guessing Game Heats Up - Mar 9, 2006 Teva itself is working on a pill version of its injectable MS drug Copaxone. Although Teva specializes in generic drugs, brand-name Copaxone is its biggest ... TheStreet.com - TheStreet.com (subscription) Teva Moves Ahead on MS Pill - May 1, 2007 Teva tried to develop a pill version of its injectable Copaxone, ... Although Teva specializes in generic drugs, it also sells Copaxone for MS and Azilect ... TheStreet.com - TheStreet.com (subscription) Teva says Copaxone fails to arrest Lou Gehrig's - Mar 13, 2008 NEW YORK, March 13 (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.O) on Thursday said its Copaxone multiple sclerosis drug failed to improve symptoms ... Reuters COPAXONE(R) Only MS Therapy Available Without Warnings or … - Mar 20, 2005 Given the recent news surrounding the multiple sclerosis (MS) therapies, Teva Neuroscience announced today that COPAXONE(R) (glatiramer acetate injection) ... Medical News Today - Medical News Today (press release) Report bodes well for Teva's MS drug - May 8, 2006 The patients on Copaxone also had a relapse rate reduction of more than 80 percent, ... "Copaxone provides RRMS patients with a treatment option that has ... Bizjournals.com Teva: A Favored Pharma - Sep 18, 2007 In North America, Copaxone is currently marketed by Teva and distributed by Sanofi-Aventis (SNY). Teva indicates that it will assume full responsibility for ... BusinessWeek COPAXONE(R) Demonstrated Protection Against Neuronal Injury in … - Nov 15, 2005 KANSAS CITY, MO -- (MARKET WIRE) -- 11/15/05 -- Clinical research data published in the December issue of Multiple Sclerosis provided evidence that ... Web Services Journal - Web Services Journal Teva claims that Novartis stole secrets of MS drug Copaxone - Sep 7, 2008 By Yoram Gabison. Forty-five days after Sandoz, a member of the Novartis group, and Momenta filed for approval of their generic version of Copaxone, ... ×”×?רץ Bayer's Betaferon Doesn't Work Better at Higher Dose - Oct 29, 2007 ...than the 250-microgram form or Teva Pharmaceutical Industries Ltd.'s Copaxone, Leverkusen, Germany-based Bayer said in an e-mailed statement today. ... Bloomberg Revenue Climbs at Teva - Feb 28, 2006 Although Teva specializes in generics, the Israel-based company's sales highlight last year was Copaxone, its brand-name treatment for multiple sclerosis. ... TheStreet.com - TheStreet.com (subscription) Twenty-Six Year Data With COPAXONE(R) Reinforce Clinical Efficacy … - Oct 3, 2005 KANSAS CITY, MO -- (MARKET WIRE) -- 10/03/05 -- Clinical experience and study data with COPAXONE® (glatiramer acetate injection) in relapsing-remitting ... Web Services Journal - Web Services Journal Copaxone inventor Ruth Arnon taking BiondVax public - Apr 22, 2007 Ruth Arnon, an immunology professor and one of the scientists behind the development of Copaxone to treat relapsing/remitting multiple sclerosis, ... Ha'aretz Q3 2005 Teva Pharmaceutical Earnings Conference Call - Part 1. - Nov 8, 2005 On the branded side, Copaxone reached all-time highs in terms of in market sales ... I would like now to turn to Copaxone, which had an outstanding quarter. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Study shows Teva's Copaxone besting other MS drugs - Apr 18, 2008 Teva Neuroscience Inc. announced positive results from a five-year study measuring the long-term effects of its multiple sclerosis drug, Copaxone, ... Bizjournals.com The Columbus Dispatch - Local/State | The Columbus Dispatch - Jul 23, 2006 Boggild and his colleagues combined it with Copaxone, a slow-acting drug. "We decided to overlap the treatments because we wanted to give some time to ... Columbus Dispatch … company Natco launches first generic competition to Teva's Copaxone... - May 20, 2007 Teva launched Copaxone - the first non-interferon treatment for multiple sclerosis - in ... Copaxone was responsible for 8.5% of Teva's turnover last year. ... Ha'aretz Teva Profit Doubles on US Generic Medicine Sales - Aug 8, 2006 Teva's multiple sclerosis treatment Copaxone contributed $353 million to Teva's ... Copaxone and Azilect, a Parkinson's treatment, are Teva's only branded ... Bloomberg Teva drug faces generic threat - Jun 12, 2008 Teva Pharmaceutical Industries, the biggest maker of generic drugs and the scourge of the Big Pharma innovators, has found its own flagship drug Copaxone ... Ha'aretz TheStreet.com Staff Reporter - Feb 15, 2005 ...a 26% gain to $261 million for Copaxone, the company's brand-name drug for treating multiple sclerosis; and contributions from the generic drug company ... TheStreet.com - TheStreet.com (subscription) Teva Guides In Line - Feb 12, 2007 For the full year, Copaxone produced $1.41 billion in sales, up 20% from 2005. Copaxone accounts for one-sixth of corporate revenue and, because its profit ... TheStreet.com - TheStreet.com (subscription) Article: Teva profit doubles on Copaxone salesMOVERSMARKETPLACE … - Aug 9, 2006 Teva profit doubles on Copaxone salesMOVERSMARKETPLACE by Bloomberg ... find International Herald Tribune articles. Alex Kuli International Herald Tribune ... Pay-Per-View - International Herald Tribune - HighBeam Research Nasal spray clears Alzheimer's brain plaques - Aug 11, 2005 They decided on a combination of glatiramer acetate (Copaxone), an approved MS drug that acts as a decoy for errant immune-system attacks, and Protollin, ... New Scientist Teva Reports Third Quarter 2007 Results.(Financial report) - Oct 30, 2007 Record-breaking global in-market sales for Copaxone([R]) of $441 million; ... Global in-market sales of Copaxone([R]) amounted to $441 million, ... Free with registration - Business Wire - AccessMyLibrary.com Investors Sell Teva after Profit Surge - Nov 7, 2006 Teva had improved sales in products such as the multiple sclerosis drug Copaxone, whose global sales for the quarter were $354 million, an increase of 15% ... BusinessWeek … Reports First Quarter 2005 Results; Copaxone Becomes US Prescriptio... - Mar 31, 2005 Net income for the first quarter of 2005 reached $259 million and $0.38 per share, while in the comparable quarter, which included one-time charges mainly ... businesswire.com Treatment With COPAXONE(R) Plus Minocycline Showed Substantial … - May 4, 2007 New data from a randomized, double-blind study showed that a combination of COPAXONE® (glatiramer acetate injection) along with the oral antibiotic ... RedOrbit Teva Pharma 1Q profit falls on charge but tops estimate - May 6, 2008 ...blood pressure medicine Lotrel, the launch of a generic version of osteoporosis drug Fosamax and strong sales of multiple sclerosis treatment Copaxone. ... Boston Globe COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment- … - Jun 20, 2006 KANSAS CITY, Mo., June 20 /PRNewswire/ -- Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron(R) (interferon beta-1b) to ... Free with registration - PR Newswire - AccessMyLibrary.com Some drug prices go up after rivals leave market ; Drugmakers say … - Jun 6, 2005 Copaxone wholesale prices also rose 9.4% in October, says Kevin Mannix of Teva Pharmaceutical Industries. Avonex's recent price increase "is not related to ... Pay-Per-View - USA TODAY - ProQuest Archiver Teva 2nd-qtr profit rises 5.3 pct on higher sales - Aug 1, 2007 Global in-market sales of Copaxone increased 23 percent to $436 million. Teva said that as of July 30 it had 153 abbreviated new drug applications awaiting ... Reuters Teva hiked Copaxone by 12.5%, claims analyst - Mar 13, 2008 By Yoram Gabison .Cacciatore recommends buying Teva shares at present and has given the share an Outperform rating, noting that Teva will be receiving 55% ... Ha'aretz Teva Has Billion-Dollar Loss - May 10, 2006 Teva said sales of its multiple sclerosis drug Copaxone rose 29% from a year ago ... "This was an especially good quarter for Copaxone, which continues to ... TheStreet.com - TheStreet.com (subscription) … Reports First Quarter 2005 Results; Copaxone Becomes US Prescriptio... - May 3, 2005 Net income for the first quarter of 2005 reached $259 million and $0.38 per share, while in the comparable quarter, which included one-time charges mainly ... $4.95 - Business Wire - ECNext … in Annals of Neurology Found COPAXONE(R) Significantly Delayed … - Feb 27, 2007 Data from the entire population also showed that COPAXONE([R]) reduced the burden and ... COPAXONE([R]) is indicated for the reduction of the frequency of ... Free with registration - Business Wire - AccessMyLibrary.com Teva's Q2 profit rises, beats expectations - Jul 29, 2008 Global in-market sales of Teva's multiple sclerosis treatment Copaxone ... Teva said its Copaxone distribution agreement with Sanofi-Aventis (nyse: SNY ... Forbes Teva Announces That Higher Dose of Copaxone(R) Showed Increased … - Apr 5, 2006 A new, higher dose of Copaxone(R) (glatiramer acetate injection) showed promising results in the treatment of patients with relapsing-remitting multiple ... Genetic Engineering News - Genetic Engineering News (press release) Rivals Benefit From Biogen Drug Recall - Mar 1, 2005 Copaxone, which acts differently than the older MS drugs, has forged into second ... Rauch, who has a hold rating on Teva, said Copaxone will maintain its ... TheStreet.com - TheStreet.com (subscription) Co-Payments for Expensive Drugs Soar - New York Times - Apr 14, 2008 She had been taking Copaxone since multiple sclerosis was diagnosed in 2000, buying a 30 days' supply at a time. And even though the drug costs $1900 a ... New York Times Analyst sees Copaxone revenues diving from 2013 - Jul 17, 2008 By Yoram Gabison. Making a viable copy of Copaxone won't be easy, so Dr. Ronny Gal doesn't believe that Teva Pharmaceutical Industries faces a true threat ... Ha'aretz COPAXONE(R) Pre-Filled Syringe Can Now Be Stored for up to One … - Jun 6, 2007 JERUSALEM & PARIS -- Teva Pharmaceutical Industries, Ltd. and sanofi-aventis today announced that the application for up to one month room temperature ... Free with registration - Business Wire - AccessMyLibrary.com Teva profit up as Copaxone sales rise 28 percent. - Nov 6, 2008 Teva profit up as Copaxone sales rise 28 percent. Byline: Michal Yoshai6 Nov Nov. 6--Generic pharmaceutical firm Teva Pharmaceutical Industries Ltd. ... $9.94 - Knight Ridder/Tribune Business News - Alacra Store New Data Confirmed Antibodies To Copaxone(R) Do Not Impact Its … - Oct 6, 2006 New data presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, ... Medical News Today - Medical News Today (press release) Market solidly green as US bailout plan helps the banks - MarketWatch - Jul 14, 2008 Teva's chief executive, Shlomo Yanai, told the Israeli daily Ma'ariv in Monday's edition that Teva doesn't expect a generic version of Copaxone to come to ... MarketWatch … Study Shows Good Efficacy and Safety for Copaxone in MS: Presented... - Oct 5, 2005 By Bruce Sylvester. THESSALONIKI, GREECE -- October 5, 2005 -- A 3-year study of patients with relapsing-remitting multiple sclerosis (RRMS) in Russia using ... DG News … (TEVA) Says Data Shows COPAXONE May Slow Neurodegenerative … - Oct 2, 2006 Teva Pharma (Nasdaq: TEVA) announces data presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple ... StreetInsider.com - StreetInsider.com (subscription) … Significant and Sustained Efficacy Of COPAXONE(R) Alone Following ... - Sep 29, 2006 A new study showed that continuing treatment with COPAXONE(R) (glatiramer acetate injection) alone, produced pronounced, early and sustained effects on ... Genetic Engineering News - Genetic Engineering News (press release) Article: Copaxone pushes Teva profits past $1 billion mark in 2005 - ... - Mar 1, 2006 Copaxone pushes Teva profits past $1 billion mark in 2005 ... find Jerusalem Post articles. SHARON WROBEL Jerusalem Post 03-01-2006 Headline: Copaxone ... Pay-Per-View - Jerusalem Post - HighBeam Research … Teva Pharmaceutical's (ADR) (TEVA) COPAXONE(R) Reduces Replapse … - Oct 12, 2007 Teva Pharmaceutical Industries (ADR) (Nasdaq: TEVA) today announced that a long-term study showed COPAXONE(R) significantly slows progression of disability ... StreetInsider.com - StreetInsider.com (subscription) M&A, rate hopes lift Europe shares in early trade - Oct 29, 2007 O) Copaxone. At 0905 GMT, the FTSEurofirst 300 .FTEU3 index of top European shares was up 0.7 percent at 1.587.42 points. Europe's benchmark index is up 7 ... Reuters COPAXONE Showed Greatest Reduction in Long-Term Relapse Rate … - Jun 21, 2005 KANSAS CITY, Mo., June 21 /PRNewswire/ -- A four-year study using a prospectively structured clinical database to assess comparative efficacy and safety of ... $4.95 - PR Newswire - ECNext REVISED: Glatiramer Acetate Reduced Relapses and Stabilized … - May 31, 2006 ..."Our data demonstrated the benefits of Copaxone(R) in reducing relapse rate in ... While on Copaxone(R) therapy, patients were seen every six months for ... DG News Teva hopes to repeat Copaxone success with newly approved … - May 19, 2006 Teva hopes to repeat Copaxone success with newly approved Parkinson's drug ... find Jerusalem Post articles. JUDY SIEGEL Jerusalem Post 05-19-2006 Headline: ... Pay-Per-View - Jerusalem Post - HighBeam Research … -Market First Quarter Sales of Its Blockbuster Copaxone(R) Increased... - May 5, 2006 Once again, Copaxone(R) was the fastest growing multiple sclerosis (MS) therapy ... According to IMS data in the US, Copaxone(R) continued to strengthen its ... Genetic Engineering News - Genetic Engineering News (press release) Multiple Sclerosis, COPAXONE(R) may repair nerve damage - Nov 19, 2005 Clinical research data published in the December issue of Multiple Sclerosis provided evidence that COPAXONE(R) (glatiramer acetate injection) may offer ... Medical News Today - Medical News Today (press release) Teva predicts 2008 earnings of $2.69 to $2.75 per share - Jul 31, 2008 In addition, Copaxone has proven to be an unprecedented success, he said, and the firm has captured a 26% slice of the global market. ... ×”×?רץ CHOLESTEROL DRUG HOPE IN MS FIGHT - Mar 17, 2006 Copaxone has been found to prevent this happening in many patients and is already approved for treating MS. Dr Olaf Stuve, who led the US study, ... Scottish Daily Record … of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More … - Oct 25, 2007 The total lifetime costs per patient for COPAXONE([R]) were estimated to be 14 ... Current data suggest COPAXONE([R]) is a selective MHC class II modulator. ... $4.95 - Business Wire - ECNext Drug is designed for specific MS patients - Oct 11, 2007 ..."We identified two genes with a high potential for determining the response to Copaxone. "In the future, it may be possible to use this method to scan the ... United Press International Teva's Copaxone hits global sales record. - Oct 31, 2006 NEW YORK (AFX) - Generic drug maker Teva Pharmaceutical Industries Ltd. said early Tuesday global sales of its multiple sclerosis drug Copaxone rose 15 ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Copaxone (Glatiramer Acetate) Demonstrated Protection Against … - Nov 14, 2005 KANSAS CITY, MO -- November 14, 2005 -- Clinical research data published in the December issue of Multiple Sclerosis provided evidence that Copaxone ... DG News FDA nixes another rival to Teva's MS drug Copaxone. - Mar 16, 2005 Following the affair of Biogen and Elan's Tysabri, the market for multiple sclerosis drugs is being examined with a magnifying glass by the US Food and Drug ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com … Showed That Higher Dose of COPAXONE(R) Increased Efficacy in … - Apr 17, 2007 A 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40 mg dose of COPAXONE(R) given daily to the currently ... Genetic Engineering News - Genetic Engineering News (press release) Teva leaps on Azilect breakthrough - Jun 18, 2008 Teva's Copaxone, a treatment for remitting/relapsing multiple sclerosis, became the No. 1 global treatment for multiple sclerosis in the first quarter, ... Ha'aretz Early Treatment with COPAXONE(R) Significantly Delayed Progression to... - Apr 16, 2008 Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced new results from the PreCISe study, which demonstrated that early treatment with ... Genetic Engineering News - Genetic Engineering News (press release) Teva's Multiple Sclerosis Pill Reduced Brain Lesions in Trial - Jun 19, 2008 Teva, which sells the Copaxone MS drug, is competing with Germany's Merck KGaA ... The patent on Copaxone, Teva's top- selling medicine, ends in six years, ... Bloomberg COPAXONE(R) Significantly Decreases Disease Activity in Patients Who ... - Oct 23, 2007 Patients treated with interferon beta (IFNb) who have experienced loss of efficacy due to the development of neutralizing antibodies, had a significant ... Genetic Engineering News - Genetic Engineering News (press release) Press Release: COPAXONE(R) Produced Significantly Greater Reduction … - Jun 9, 2005 COPAXONE(R) Produced Significantly Greater Reduction in Relapse Rate Compared to Beta Interferon Therapies. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … Efficacy and Safety of COPAXONE(R); COPAXONE(R) Only MS Therapy … - Mar 18, 2005 Multiple Studies Demonstrate Efficacy and Safety of COPAXONE(R); COPAXONE(R) Only MS Therapy Available Without Warnings or Precautions for Liver Damage. Pay-Per-View - PR Newswire - HighBeam Research … Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the... - Mar 11, 2008 Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple ... Pay-Per-View - PR Newswire - HighBeam Research … Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost- … - Apr 11, 2007 Current data suggest COPAXONE([R]) is a selective MHC class II modulator. COPAXONE([R]) is indicated for the reduction of the frequency of relapses in RRMS. ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Long-Term Copaxone(R) Study Showed 92% of Multiple … - May 8, 2006 Long-Term Copaxone(R) Study Showed 92% of Multiple Sclerosis Patients Were Still Walking Unaided After a Mean of 10 Years on Treatment. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research The blend of drugs that can 'stop MS in its tracks' - Jul 24, 2006 Copaxone also suppresses the body's immune response and helps to protect the nerve cells from further damage. Dr Boggild added: "This is not a cure, ... Daily Mail Press Release: COPAXONE(R) Reduced Relapses and Stabilized … - May 31, 2006 COPAXONE(R) Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When Avonex(R) Failed. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research … New Thinner 29-Gauge Needle For COPAXONE® Pre-Filled Syringe - Dec 30, 2008 Teva (NASDAQ:TEVA) today announced the launch of a new, thinner, 29-gauge pre-filled syringe for its multiple sclerosis (MS) treatment, COPAXONE® ... Medical News Today - Medical News Today (press release) Analysts remain optimistic on Teva - Feb 18, 2005 He remained optimistic, however, that when the dust settles Copaxone would not ... "However, Copaxone overcame the same pessimistic talk in 2002 with the ... Pay-Per-View - Jerusalem Post - ProQuest Archiver Study Showed Treatment With COPAXONE(R) is Associated With … - Sep 12, 2006 A retrospective analysis of multiple sclerosis (MS) patients comparing patients treated with immunomodulatory agents with untreated patients revealed that ... RedOrbit Press Release: COPAXONE Showed Greatest Reduction in Long-Term … - Jun 21, 2005 COPAXONE Showed Greatest Reduction in Long-Term Relapse Rate Among MS Treatments. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: COPAXONE(R) May Have Ability to Protect Against … - Jun 30, 2005 COPAXONE(R) May Have Ability to Protect Against Axonal Injury Over the Long-Term in Relapsing-Remitting Multiple Sclerosis. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Q2 2005 Teva Pharmaceutical Earnings Conference Call - Final. - Aug 1, 2005 We had very strong performances with all-time highs in Copaxone sales as well ... Global end-market sales of Copaxone were outstanding -- sales reached $291 ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Multiple Studies Demonstrate Efficacy and Safety of COPAXONE(R) - Mar 18, 2005 KANSAS CITY, MO -- (MARKET WIRE) -- 18-03-2005 -- Given the recent news surrounding the multiple sclerosis (MS) therapies, Teva Neuroscience announced today ... Pay-Per-View - Market Wire - Factiva, from Dow Jones Momenta Claims Teva Gave Conflicting Information On Copaxone - Nov 14, 2008 Momenta Pharmaceuticals Inc. (MNTA) is accusing Teva Pharmaceutical Industries Ltd. (TEVA) of providing conflicting information to regulators to secure ... Lifescience-online |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |